PTGS2 and arthritic joint disease: Andrographolide treated CFA-induced arthritis by inhibiting the expression of a series of arthritis-related molecules, including COX-2, NF-κB, p-p38, CD40, TNF-α, IL-1β, and IL-6 (Gupta et al., 2020).